Abstract
Most countries have enacted some restrictions to reduce social contacts to slow down disease transmission during the COVID-19 pandemic. For nearly two years, individuals likely also adopted new behaviours to avoid pathogen exposure based on personal circumstances. We aimed to understand the way in which different factors affect social contacts – a critical step to improving future pandemic responses. The analysis was based on repeated cross-sectional contact survey data collected in 21 European countries between March 2020 and March 2022. We calculated the mean daily contacts reported using a clustered bootstrap by country and by settings (at home, at work, or in other settings). Where data were available, contact rates during the study period were compared with rates recorded prior to the pandemic. We fitted censored individual-level generalized additive mixed models to examine the effects of various factors on the number of social contacts. The survey recorded 463,336 observations from 96,456 participants. In all countries where comparison data were available, contact rates over the previous two years were substantially lower than those seen prior to the pandemic (approximately from over 10 to <5), predominantly due to fewer contacts outside the home. Government restrictions imposed immediate effect on contacts, and these effects lingered after the restrictions were lifted. Across countries, the relationships between national policy, individual perceptions, or personal circumstances determining contacts varied. Our study, coordinated at the regional level, provides important insights into the understanding of the factors associated with social contacts to support future infectious disease outbreak responses.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The following funding sources are acknowledged as providing funding for the named authors. HPRU in Modelling & Health Economics (NIHR200908: KLMW); European Union Horizon 2020 research and innovation programme (EpiPose 101003688: AG, WJE); European Research Council under the European Union Horizon 2020 research and innovation programme (TransMID 682540: CF, PB, NH) This research was partly funded by the Global Challenges Research Fund (GCRF) project RECAP managed through RCUK and ESRC (ES/P010873/1: CIJ) NIHR (PR_OD_1017_20002: WJE) UK MRC (MC_PC_19065 - Covid 19: Understanding the dynamics and drivers of the COVID-19 epidemic using real-time outbreak analytics: WJE). In Belgium, CoMix data collection in Belgium was made possible with financial support of Janssen Pharmaceuticals and the national public health institute of Belgium, Sciensano. In Germany, the COVIMOD project is funded by intramural funds of the Institute of Epidemiology and Social Medicine, University of Munster, and of the Institute of Medical Epidemiology, Biometry and Informatics, Martin Luther University Halle-Wittenberg, as well as by funds provided by the Robert Koch Institute, Berlin, the Helmholtz-Gemeinschaft Deutscher Forschungszentren e.V. via the HZEpiAdHoc "The Helmholtz Epidemiologic Response against the COVID-19 Pandemic" project, the Saxonian COVID-19 Research Consortium SaxoCOV (co-financed with tax funds on the basis of the budget passed by the Saxon state parliament), the Federal Ministry of Education and Research (BMBF) as part of the Network University Medicine (NUM) via the egePan Unimed project (funding code: 01KX2021) and the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation, project number 458526380).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Participation in this opt-in study was voluntary, and all analyses were carried out on anonymised data. In the UK, the study was approved by the ethics committee of the London School of Hygiene and Tropical Medicine (Reference number: 21795). In Belgium, the study was approved by Ethical Comimtte of the University Hospital Antwerp. In The Netherlands, waiver was obtained from Medische Ethische Toetsingscommissie Utrecht. In Austria, the study was waived by Ethikkommission der Stadt Wien. In Denmark, waiver was obtained from The Central Denmark Region Committees on Health Research Ethics. In France, waiver was obtained from Direction centrale du renseignement interieur Centre Hospitalier Universitaire de Poitiers. In Poland, the study was approved by Komisja Bioetyczna, Narodowego Instytutu Zdrowia Publicznego, Panstwowego Zaldadu Higieny, Warszawa. In Portugal, the study was approved by Comissao de Etica para a Saude do Instituto Nacional de Saude Doutor Ricardo Jorge. In Spain, the study was approved by Comite dEtica de la Investigacion del Hospital Universitari Germans Trias i Pujol. In Italy, the study was approved by Comitato di Bioetica d' Ateneo, Universita degli studi di Torino. In Finland, waiver was obtained from Institutional Review Board of the Finnish Institute for Health and Welfare. In Switzerland, the study was approved by Gesundheits-, Sozial- und Integrationsdirektion Kantonale Ethikkommission fur die Forschung. In Lithuania, waiver was obtained from the Lithuanian Bioethics Committee. In Greece, the study was approved by Research Ethics Committee and University of West Attica. In Slovenia, the study was approved by Komisija Republike Slovenije za medicinsko etiko. In Croatia, the study was approved by Etiko povjerenstvo Hrvatskog zavoda za javno zdravstvo. In Estonia, the study was approved by Research Ethics Committee of the National Institute for Health Development. In Hungary, the study was approved by Health Science Council - Scientific and Research Ethics Committee Budapest. In Slovakia, the study was approved by Eticka komisia Univerzita Komenskeho v Bratislave Jesseniova lekarska fakulta v Martine.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* kerry.wong{at}lshtm.ac.uk
Data Availability
